The FDA approved dostarlimab in rectal cancer and pembrolizumab in tumors with high mutational burden, Europe cleared teclistamab in myeloma, and more.
News|Videos|June 16, 2024
Comparative Efficacy of Bruton Tyrosine Kinase Inhibitors in the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia: A Network Meta-Analysis
Author(s)Mazyar Shadman, MD, MPH
This is an evaluation of the results of a network meta-analysis covering the comparative efficacy of bruton tyrosine kinase Inhibitors in relapse/refractory chronic lymphocytic leukemia.
Advertisement
Advertisement
Related to this article
Lisaftoclax plus acalabrutinib earned breakthrough therapy status in China for untreated CLL/SLL.
The top 5 OncLive TV videos of the week cover insights in multiple myeloma, HR+ breast cancer, CAR T-cell therapy, CLL, and oral SERDs.
The FDA expands nogapendekin alfa inbakicept in bladder cancer, European regulators back daraxonrasib in pancreatic cancer, and more.
The FDA set a PDUFA target action date of March 31, 2027, for tabelecleucel in relapsed or refractory EBV-positive posttransplant lymphoproliferative disease.
The top 5 OncLive TV videos of the week.
Advertisement
Advertisement
Trending on OncLive
1
Adjuvant Giredestrant Preserves QOL With Sustained Tolerability in ER+, HER2– Early Breast Cancer
2
Sacituzumab Govitecan Triplet Elicits Durable Responses in Treatment-Naive Metastatic Urothelial Cancer
3
Perioperative Enfortumab Vedotin Plus Pembrolizumab Improves ctDNA Clearance in Cisplatin-Eligible MIBC
4
Ad Hoc Analysis Supports Contributions of Both Enfortumab Vedotin and Pembrolizumab in Cisplatin-Ineligible MIBC
5